Lupron Depot 7.5 mg (Leuprolide Acetate for Depot Suspension) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Lupron Depot 7.5

Endometriosis »

What is endometriosis?

Endometriosis is the abnormal growth of cells (endometrial cells) similar to those that form the inside of the uterus, but in a location outside of the uterus. Endometrial cells are cells that are shed each month during menstruation. The cells of endometriosis attach themselves to tissue outside the uterus and are called endometriosis implants. These implants are most commonly found on the ovaries, the Fallopian tubes, outer surfaces of the uterus or intestines, and on the surface lining of the pelvic cavity. They can also be found in the vagina, cervix, and bladder, although less commonly than other locations in the pelvis. Rarely, endometriosis implants can occur outside the pelvis, on the liver, in old surgery scars, and even in or around the lung or brain. Endometrial implants, while they can cause problems, are benign (not cancerous).

Who is affected by endometriosis?

Endometriosis affects w...

Read the Endometriosis article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Lupron Depot 7.5 mg User Reviews >>

Lupron Depot 7.5 mg

Prostate Cancer Slideshow Pictures

Medical Illustrations of the Prostate Image Collection

Screening Tests Every Man Needs Slideshow Pictures

font size

OVERDOSE

There is no experience of overdosage in clinical trials. In rats, a single subcutaneous dose of 100 mg/kg (approximately 4,000 times the estimated daily human dose based on body surface area), resulted in dyspnea, decreased activity, and excessive scratching. In early clinical trials with daily subcutaneous leuprolide acetate, doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.

CONTRAINDICATIONS

LUPRON DEPOT is contraindicated in individuals with known hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT. Reports of anaphylactic reactions to GnRH agonist analogs have been reported in the medical literature.
LUPRON DEPOT may cause fetal harm when administered to a pregnant woman. Expected hormonal changes that occur with LUPRON DEPOT increase the risk for pregnancy loss and fetal harm when administered to a pregnant woman (see Pregnancy Category X). LUPRON DEPOT is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Last reviewed on RxList: 3/14/2012
This monograph has been modified to include the generic and brand name in many instances.